



Bone Marrow Adipocytes: The Enigmatic
Components of the Hematopoietic Stem Cell Niche
Vincent Cuminetti 1 and Lorena Arranz 1,2,3,*
1 Stem Cell Aging and Cancer Research Group, Department of Medical Biology, Faculty of Health Sciences,
UiT – The Arctic University of Norway, 9019 Tromsø, Norway; vincent.cuminetti@uit.no
2 Department of Hematology, University Hospital of North Norway, 9019 Tromsø, Norway
3 Young Associate Investigator, Norwegian Center for Molecular Medicine (NCMM), University of Oslo,
0349 Oslo, Norway
* Correspondence: lorena.arranz@uit.no; Tel.: +47-7762-0841
Received: 16 April 2019; Accepted: 16 May 2019; Published: 18 May 2019


Abstract: Bone marrow adipocytes (BMA) exert pleiotropic roles beyond mere lipid storage and
filling of bone marrow (BM) empty spaces, and we are only now beginning to understand their
regulatory traits and versatility. BMA arise from the differentiation of BM mesenchymal stromal
cells, but they seem to be a heterogeneous population with distinct metabolisms, lipid compositions,
secretory properties and functional responses, depending on their location in the BM. BMA also
show remarkable differences among species and between genders, they progressively replace the
hematopoietic BM throughout aging, and play roles in a range of pathological conditions such as
obesity, diabetes and anorexia. They are a crucial component of the BM microenvironment that
regulates hematopoiesis, through mechanisms largely unknown. Previously considered as negative
regulators of hematopoietic stem cell function, recent data demonstrate their positive support for
hematopoietic stem cells depending on the experimental approach. Here, we further discuss current
knowledge on the role of BMA in hematological malignancies. Early hints suggest that BMA may
provide a suitable metabolic niche for the malignant growth of leukemic stem cells, and protect
them from chemotherapy. Future in vivo functional work and improved isolation methods will
enable determining the true essence of this elusive BM hematopoietic stem cell niche component, and
confirm their roles in a range of diseases. This promising field may open new pathways for efficient
therapeutic strategies to restore hematopoiesis, targeting BMA.
Keywords: Bone marrow adipocytes; mesenchymal stromal cells; hematopoietic stem cells; hematopoietic
stem cell niche; hematopoiesis; hematopoietic malignancies; metabolism
1. Introduction
Bone marrow adipocytes (BMA) were first seen in the 19th century, when Franz Ernst Christian
Neumann observed red and yellow regions in the bone marrow (BM). One century later, adipocytes
were identified as the major cell component of the yellow marrow [1]. In adults, BMA represent
between 50 and 70 percent of the BM volume, and about 5 percent of whole body fat [2]. BMA are also
present in the red marrow, in charge of the process of hematopoiesis or blood cell formation, including
a variety of cell subsets such as erythrocytes, platelets and leukocytes, i.e., lymphocytes, monocytes and
granulocytes [3]. These highly specialized and heterogeneous cell subsets arise from the differentiation
of hematopoietic stem cells (HSC), located at the top of the blood system hierarchy [4]. HSC reside in
particular microenvironments or niches in the BM, which are defined as the close environments in the
vicinity of HSC with a variety of cell types and molecules that exert a fine-tuned regulation of HSC
survival, self-renewal, differentiation and retention [5,6]. In the BM, HSC are found preferentially in
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perivascular niches, mostly sinusoids, formed by mainly endothelial cells and mesenchymal stromal
cells (MSC) [7,8]. A smaller fraction of HSC localizes adjacent to small-diameter arterioles, adjacent to
neural/glial antigen 2+ periarteriolar cells and MSC [7,9,10]. However, a variety of cell types have been
involved in HSC regulation, including BMA [11]. Interestingly, although BMA have been traditionally
considered as negative regulators of the HSC niche [11], more recent data point to BMA as key players
during hematopoietic regeneration [12].
BMA are heterogeneous in terms of development, size, numbers, lipid composition, genomic
expression and localization [13]. Heterogeneity depends on factors such as species, mouse strain [13] and
gender [14]. Accumulation of BMA relates to pathogenesis in several disorders such as osteoporosis [15,16]
and type II diabetes [17]. In this scenario, the purpose of this review is to integrate the current knowledge
on BMA physiological functions and their involvement in disease mechanisms, with a focus on identifying
gaps in the literature and generating interest in BMA potential as targets of future therapeutic strategies.
2. BMA: Human versus Mouse Features
During the 1980s, development of magnetic resonance imaging (MRI) and its use to study BM
disorders allowed better characterization of BMA distribution [18]. In humans, at birth, the marrow is
fully hematopoietic and contains no adipocytes. Early in life, a process of conversion of hematopoietic
to fatty marrow takes place from distal towards central skeleton that continues throughout aging [19].
In long bones, tissue replacement starts in diaphysis with relative preservation of metaphyseal
hematopoiesis. In the femur diaphysis, for example, conversion happens in 10 year-old children,
followed by the distal metaphysis after 20 years. Femoral BM adiposity has an adult pattern after 24
years [20]. At the end of adolescence, hematopoietic marrow remains in the proximal metaphysis of
femur and humerus as well as in spine, sternum, ribs, and skull. BMA arise later in the axial skeleton
along the central axis, but in adults, they are present in the red marrow of sternum, ribs, pelvis and
vertebral bones [21]. In the spine, BM adiposity grows from 27% to 70% in individuals between 10
and 76 years of age [22]. The rate of conversion may vary in other areas such as sacrum and BMA
expansion towards lumbar vertebrae [22,23]. In contrast, the heel does not correlate with aging, as it
contains already around 83% BMA in 10 year-old children, indicative of the much earlier onset of
conversion in peripheral skeleton [22]. However, the process may be reverted in the extremities at any
age in case of sustained increase in demand of hematopoiesis [22].
Rodents have lower BM adiposity than humans, but their BMA expansion follows similar centripetal
pattern. Different types of BMA were already observed 40 years ago by Mehdi Tavassoli, when he
suggested that adipocytes from red and yellow marrow are differentially affected by hemolysis and
have distinct lipid composition [24,25]. These observations where recently confirmed when Scheller et al.
defined two groups of adipocytes that differ in their location and response to physio-pathological
conditions [13]. Constitutive BM adipose tissue (cBMAT) localizes in distal tibia and caudal vertebrae.
These adipocytes develop very early after birth in the yellow marrow, occupy most of the BM cavity and
are similar to adipocytes in white adipose tissue. In the proximal tibia near fibula junction, femur and
axial skeleton, BMAT develops later, it is found as single or clustered smaller adipocytes interspersed with
hematopoietic cells, and it responds to a range of nutritional, environmental, genetic, and endocrine factors.
This is the regulated BMAT (rBMAT). Adipocytes from rBMAT reduce size and number after for example
three weeks of cold exposition [13], fasting [26] or prolonged exercise [27], but also during lactation [28]
or hematological malignancy such as acute myeloid leukemia (AML) [29]. Conversely, conditions
that increase size and number of rBMAT include aging, high fat diet, caloric restriction and anorexia,
irradiation, or treatments with hypoglycemic thiazolidinediones (insulin-mimetic drugs used for type 2
diabetes treatment) and hyperglycemic glucocorticoids [17,30]. Thus, seemingly opposed conditions
from the metabolic perspective result in similar rBMAT expansion. Importantly, characterization of BMA
subtypes in humans is yet to be done.
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3. Sources of BMA
BMA develop from MSC differentiation in the BM, which can also differentiate into chondroblasts
and osteoblasts [31]. MSC were functionally defined by the International Society of Cellular Therapy as
plastic-adherent, they show expression of CD105 CD73 CD90, and lack expression of CD45 CD34, CD14
or CD11b, CD79α or CD19, and HLA-DR surface molecules, and must have the ability to differentiate
into osteoblasts, adipocytes and chondroblasts in vitro [32]. Thus, MSC functionality has mainly been
studied in vitro, so the adipocyte lineage in the BM is not completely clear yet, particularly in humans.
In mice, MSC in neonatal BM develop during embryogenesis from Osterix1-expressing cells [33],
and from leptin receptor-expressing cells in adult BM [34]. In adult mice, MSC have been defined
by their ability of tri-lineage differentiation in vitro, activity of colony forming unit fibroblast, lack of
expression of CD45 CD31 Ter119, and showing expression of different markers such as leptin receptor,
Pdgfr-α Sca-1, or nestin [34–37]; all of them at least partially overlapping in their identities. Recent
lineage-tracing studies have shed further light, revealing that MSC capable of tri-lineage differentiation
in vivo are immunophenotypically defined as CD45− CD31− Sca-1+ CD24+, and also overlap with the
above [38]. Leptin receptor-cre+ cells are able to differentiate into adipocytes and osteoblasts in vivo,
but their ability to differentiate into chondrocytes is only revealed upon injury [34] (Figure 1). Further,
nearly all leptin receptor-cre+ cells express Pdgfr-α, and 12% express Sca-1 [34]. Recent single-cell
transcriptomic profiling of leptin receptor-cre+ cells shows the heterogeneity of this compartment, and
has identified four different clusters; Mgphigh and especially Lplhigh express adipogenesis-associated
markers, and Wif1high and Spp1highIbsphigh are osteo-primed [39]. Adipogenic leptin receptor-cre+
clusters can be distinguished by ESM1 staining, while osteogenic leptin receptor-cre+ clusters express
CD200 and CD63 [39]. Conversely, CD45− CD31− Sca1+ CD24+ multipotent cells express high levels of
Lepr, Scf and Vcam1, suggesting that they may represent a further purification step of MSC [38] (Figure 1).
CD45− CD31− Sca1+ CD24+ MSC give rise to CD45− CD31− Sca-1− Pdgfr-α+ osteochondrogenic
progenitors and CD45− CD31− Sca-1+ CD24− adipose progenitors, and the latter differentiate into
adipocyte precursors CD45− CD31− Sca-1− Zfp423+ [38] (Figure 1). However, no efforts were taken
to uncover the potential different origins for cBMA and rBMA. Future work will be required for
a complete understanding of mesenchymal hierarchy, from stem cells through multipotent and
oligopotent progenitors to fully differentiated cells. Single-cell transcriptome analyses together with
in vivo lineage tracing and fate mapping through barcoding will open new avenues in this field.
Interestingly, aging is linked to increased content of BMA in both human and mice [40], and also
biased differentiation of MSC towards adipocyte lineage in mice [38]. Although increased secretion
of dipeptidyl peptidase-4 (Dpp4) by adipogenic cell populations including MSC after adipogenic
differentiation, has been related to reduced bone healing in old mice, Dpp4 did not affect adipogenic
differentiation [38]. Future studies should focus on understanding the underlying mechanisms of
age-related adipogenic biased MSC differentiation, and confirm the validity of this process in humans.
Recent data suggest that BM stromal cells could also be a source of adipocyte progenitors for other
fat pads, and that BM-derived cells contribute to around 10% of cells in these sites [41]. Although these
experiments were performed under BM transplantation, they point to a potential BM origin for some
extramedullary adipocytes under steady-state conditions [42,43]. Future work is needed to understand
the mechanisms underlying adipocyte progenitor egress from BM and homing into extramedullary
sites. Adipocytes have a range of functions in the organism, such as contributing to wound healing
after skin injury in mice, where they regenerate from myofibroblasts in hair follicles [44]. Moreover,
adipocytes were recently reported to be motile in Drosophilia melanogaster, and contribute to wound
healing through peristaltic mechanisms [45]. Further investigations are required to understand these
phenomena better, particularly in mammals, but these data raise interest in the potential role of BMA
and their progenitors in extramedullary hematopoiesis and homeostasis.
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Figure 1. Adipocyte lineage in the mouse bone marrow. Stem cell-like mesenchymal stromal cells 
(MSC) capable of in vivo tri-lineage differentiation in the bone marrow are immunophenotypically 
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Figure 1. Adipocyte lineage the mouse bone marrow. Stem cell-like mesenchymal stromal cells (MSC)
capable of in vivo tri-lineage differentiatio in the bone marrow e immunophenotypicall defined
as CD45− 31− Sca-1+ CD24+, and show overlap with leptin receptor-cre+ (LepR+), Pdgfr-α(Pα)+
Sca-1+, and nestin+ cells. MSC give rise to osteochondrogenic progenitors ( ) − CD31−
Pα+ Sca-1− and adipogenic progenitors (APC) CD45− CD31− Sca-1+ CD24−. APC differentiate in
CD45− CD31− Sca-1− Zfp423+ pre-adipocytes that give rise to adipocytes [38]. LepR+ cells are able to
differentiate into adipocytes and osteoblasts in vivo, but their ability to differentiate into chondrocytes
was only observed upon injury [34].
4. BMA Metabolic Function
The well-known metabolic role of adipocytes in the organism is storage and release of lipids
depending on the energetic status. When energy intake is higher than expenses, adipocytes store
fatty acids (FA) as triglycerides under the control of insulin. When energy is required, catabolic
hormones such as adrenaline, glucocorticoids, and glucagon stimulate hydrolysis of triglycerides into
FA and glycerol [46]. The first characterization of lipids in the BM was made by Mehdi Tavassoli,
who observed that the red marrow preferentially contains myristic and palmitic acid (saturated FA)
while the yellow marrow preferentially contains myristoleic and palmytoleic acid (mono-unsaturated
FA) [25]. Comparison of lipid content in subcutaneous adipose tissue and BMA revealed that BMA
contained less mono-unsaturated FA and more saturated FA. Further characterization showed that BMA
from proximal femur had more saturated FA than BMA from proximal tibia [47]. These observations
emphasize the metabolic heterogeneity of BMA that should be the subject of future research in the
context of their regulatory activities in the BM.
Insulin and thiazolidinedione stimulate the expression of genes related to lipid metabolism in BMA
such as FA synthase, FA binding protein, hormone-sensitive lipase and FA translocase. Interestingly, they
do not induce translocation or expression of the insulin-sensible glucose transporter Glut-4, suggesting
that BMA metabolism is based on lipid rather than glucose metabolism [48]. Further, while BMA
have a lipid metabolism similar to classic adipocytes from white adipose tissue [49], they also seem to
express specific markers of brown adipocytes such as UCP-1, PGC-1α, Prdm16, FoxC2 and β3-adrenergic
receptor [50]. However, these markers are between 10,000 and 20,000 times less expressed in BMA
than in brown adipocytes from brown adipose tissues [51]. This may suggest that BMA have a mixed
metabolic phenotype between white and brown adipocytes; i.e., beige adipocytes. Nevertheless, it may
also be reflection of BMA heterogeneity, meaning that rBMA that respond to cold exposition could
have a brown-like phenotype under normal conditions while cBMA could be more similar to white
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adipocytes [14]. In this regard, thorough characterization of distinct immunophenotypical profiles for
both types of BMA will be highly valuable in the hematopoietic field.
Surprisingly, while rBMAT expand with aging and high fat diet [17,30], brown adipocyte markers
in BMA decrease with aging and diabetes, suggesting a link between BMA metabolic function and
physio-pathological conditions [50]. Aging and obesity are associated with functional impairment of
adipose tissue metabolism [52]. Accumulation of monocyte-macrophages in adipose tissue of obese
individuals is associated with low-grade chronic inflammation and development of diabetes [53,54].
At least partially, these monocytes are recruited from BM through leptin receptor signaling, as chimeric
wild-type (WT) mice reconstituted with leptin receptor-deficient BM and challenged with high-fat
diet had lower body weight, adiposity, and inflammation, together with greater insulin sensitivity,
compared with WT mice reconstituted with WT BM [55]. The potential direct cross-talk between
monocytes and BMA in the BM is yet to be elucidated. However, a shift of MSC differentiation to the
adipogenic lineage is found in diabetes and under chronic use of steroids and thiazolidinediones [56],
and mature BMA stimulate BM MSC differentiation into new fat via secretion of MCP-1 [57], thereby
potentially influencing hematopoietic output. Further, BMA are negative regulators of hematopoiesis
under normal conditions [11] so future studies on the interplay between HSC and BMA during aging
and diabetes will be highly relevant.
Intriguingly, inverse conditions to diabetes and high fat diet such as caloric restriction and
anorexia nervosa are also associated with BMA increase [58,59]. This seemingly contradiction could be
explained by the fact that the energetic cost of maintaining hematopoiesis by HSC, and producing
billions of blood cells daily, is higher than adipogenesis done by MSC. So, when energy is limited,
hematopoiesis slows down and hematopoietic cells are rapidly replaced by BMA with preservation
of tissue architecture; situation that can be restored fast when conditions change back to normal.
In addition, BMA could be understood as a fine-tuned regulated expandable-contractible fat storage in
the BM serving to minimize systemic energy requirements for sustaining optimal hematopoiesis [60].
The underlying mechanisms are not completely understood but c-kit signaling has been suggested
to couple MSC and HSC differentiation in BM. In this regard, loss of function mutations in the c-kit
receptor and membrane-bound kit-ligand result in certain hematopoietic defects such as anemia and
mast cell depletion, and absence of BMA in long bones and lumbar vertebrae [61].
During energetic demand by the organism, lipid mobilization from adipose tissue is stimulated
by adrenergic signals from the sympathetic nervous system through β-adrenergic receptors (βAR) [62].
Unlike adipose tissue, BMA exhibit little catabolic response to βAR stimulation, although resistance is
more pronounced in distal regions of the skeleton where BMA participation in hematopoiesis is less
evident [26]. Despite recent data showing that BM MSC can be a source of beige adipocytes for white
adipose tissue induced by β3AR activation [63], local responses in BM remain elusive. Interestingly,
cyclical β3AR stimulation in BM MSC inhibits their expression of Cxcl12, which results in circadian
egress of HSC and progenitors from BM [64]. In addition, damage to the microenvironment with
loss of the neural-MSC regulatory circuit results in reduction of Cxcl12 that then allows expansion of
mutant HSC in myeloproliferative neoplasms [65]. In this scenario, understanding the coordinated
effect of β3AR activation on BMA seems timely.
Additional signals might be involved in the regulation of BMA metabolism. Metabolites such
as lactate [66] and succinate [67] seem to be important players in the activation of brown adipocytes
in brown and white fat pads. Succinate is product of the tricarboxylic acid cycle, and interestingly,
its accumulation in brown adipocytes in response to cold occurs independently of AR activation.
Further, oxidation of succinate by succinate dehydrogenase initiates production of reactive oxygen
species, and drives thermogenic respiration in those cells. Pharmacological elevation of circulating
succinate drives UCP1-dependent thermogenesis by brown adipose tissue in vivo, protecting against
diet-induced obesity and improving glucose tolerance [67]. This points to succinate as a promising
therapeutic target. However, succinate is increased 24-fold in BM stromal cells derived from diabetic
mice compared to normoglycaemic mice [68]. In vitro, extracellular succinate binds to its receptor
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in osteoclastic lineage cells and stimulates osteoclast differentiation, a process that may influence
the bone resorption seen in vivo in diabetic mice [68]. Unfortunately, the potential involvement of
BMA was not studied. Succinate is also defined as an oncometabolite, with important roles in cancer,
inflammation and hematopoiesis through both cell- and non-cell-autonomous mechanisms [69]. Thus,
integrative studies on the role of succinate in hematopoiesis with potential participation of BMA will
be highly relevant.
5. Sexual Dimorphism in BMA
The use of MRI to study BM adiposity also revealed differences between men and women. A first
study showed that men between 17 and 42 years of age had higher amount of BMA in the sacrum
compared with women [23]. This observation was confirmed in a larger study with 154 healthy
subjects, that showed that the most prominent difference (12%) in marrow adiposity between men and
women occurs from 31 to 50 years of age [70]. However, beyond 50 year-old individuals, the difference
is reversed and menopausal women have 10% more BMA than age-matched men [71]. Interestingly,
estrogen-supplemented post-menopausal women keep lower BMA content, suggesting a negative role
for estrogens in BMA development [72].
These observations make sense considering that sexual dimorphism in white adipose tissue in
rats was observed almost 60 years ago [73]. Moreover, in rats, estrogens are negative regulators
of adipogenesis and central abdominal fat accumulation at least partially by inhibiting S100A6
expression [74]. Human sexual dimorphism in adipose tissue development has been extensively
studied in the context of metabolic diseases. Women have more subcutaneous fat than men, who have
more visceral fat. In obesity, men exhibit “apple-shape” android obesity, which is more deleterious
metabolically than women “pear-shape” gynoid obesity [75,76]. Visceral adipose tissue is more
deleterious metabolically due to higher lipolysis rate, lower insulin-sensitivity and portal vein drainage
of adipokines and FA towards the liver, resulting in production of inflammatory mediators such as
C-reactive protein and hepatotoxicity [77], but also in lipotoxicity of these FA in other insulin-sentive
organs, resulting in insulin-resistance [78]. Based on these observations, it is reasonable to hypothesize
that BMA are negatively regulated by estrogens in women previous to menopause, and BMA could
be similar to visceral adipocytes, but no research group has tried to compare BMA with adipocytes
located in different fat pads to date. Future work should confirm the validity of these ideas. However,
BMA size and number correlate with total body fat in premenopausal obese woman [79], suggesting
additional regulatory factors upstream of estrogens that should be subject of future work in the context
of obesity.
There is no general consensus on BMA sexual dimorphism in rodents, as marrow adiposity varies
between strains and most of the time only young animals are used in experiments. For example, C57BL/6J
mice accumulate rBMAT in proximal tibia later than C3H/HeJ mice [13]. However, the content of cBMAT
in tibia is similar between the females of both strains and, unlike women, female mice have higher rBMAT
content than males [13,14]. Marrow adiposity in rodents is regulated by estrogens. Estrogen deficiency in
ovariectomized females leads to higher content of rBMAT, with little effect on cBMAT [14,80]. Conversely,
estrogen supplementation decreases marrow adiposity [81].
In mice, estrogens are directly involved in hematopoiesis and promote HSC self-renewal through
cell-autonomous mechanisms via activation of the α-isoform of the estrogen receptor [82]. Activation of
this receptor with tamoxifen, an estrogen analog, induced apoptosis in short-term HSC and multipotent
progenitors, and promoted proliferation of long-term HSC [83]. Further, tamoxifen blocked development
of myeloproliferative neoplasm in a JAK2-V617F+-induced mouse model and enhanced chemotherapy
efficiency in an MLL-AF9+-induced mouse model of AML [83]. In this scenario, understanding the
coordinated action of estrogens in hematopoiesis both cell-autonomous on HSC and non-cell-autonomous
through BMA seems timely (Figure 2).
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Figure 2. Estrogens may exert both cell- and non-cell-autonomous effect on hematopoietic stem cells
(HSC). Estrogens directly regulate HSC self-renewal and proliferation through estrogen receptor (ER)-α
activation in HSC [82,83], but potentially also indirectly through the bone marrow HSC niche by
inhibition of mesenchymal stromal cell (MSC) differentiation into adipocytes.
The role of testosterone regulating BMA content is unknown. Testosterone level correlates
inversely with obesity, but the cause seems to be expression of aromatase by adipose tissue, which
converts testosterone in estradiol in obese men [84]. Estradiol then exerts an inhibitory loop on the
hypothalamic-pituitary axis that inhibits testosterone production. Moreover, leptin, the circulating
levels of which are increased in obesity, further inhibits testosterone production by Leydig cells [84].
The decrease in testosterone in obese men may be a risk factor in the context of metabolic syndrome,
as low testosterone correlates with insulin resistance, but the causal effect mechanism, if any, remains
unknown [85]. Recent data from in vitro experiments suggest that testosterone controls adipocyte
differentiation and metabolism [86,87], but its effect in BMA is yet to be elucidated.
6. Role of BMA in Hematop iesi : BMA as omponents of the BM HSC Niche
Like any other adult stem cell, HSC are found in specialized microenvironments called niches [7].
Richard Schofield proposed the concept of the niche in 1978, defined as the close environment of
stem cells, regulating their survival, retention, differentiation and self-renewal by a combination of
soluble factors and cell contact mechanisms [6]. Extensive work has been performed in the last 20
years to characterize the HSC niche. The team of David Scadden originally described that osteoblasts
expressing Notch ligand jagged 1 support increased numbers of HSC through activation of Notch1
in vivo [88]. The same year, osteoblasts were shown to maintain HSC anchored in the marrow by
expression of N-cadherin in osteoblasts and β-catenin in long-term HSC [89]. Later, endothelial
cells from sinusoids were found to host most HSC in the BM [90]. The HSC niche in the BM is now
better understood, and perisinusoidal niches formed by mainly MSC and endothelial cells contain
the majority (85%) of HSC [8,91] and support HSC by major production of Scf and Cxcl12 [92,93].
The endosteal niche contains progenitors of the lymphoid lineage [94], though recent data locate
common lymphoid progenitors and pro-B cells near MSC and sinusoids as well [95,96].
MSC are an essential cell component of the vascular niche, and they were originally described as
a major source of Cxcl12, which maintains HSC in the niche [93,97]. MSC have been further characterized
in vivo by use of mouse models to help trace them, i.e., leptin receptor-cre+ cells and nestin-gfp+
cells [35–37], or by prospective identification, isolation and transplantation, i.e., Pdgfr-α+ Sca-1+ cells [37].
As mentioned previously, all of these cell types are partially overlapping. Leptin receptor-cre+ MSC
labels a population of perivascular cells that are the main source of Cxcl12 and Scf in the BM, and are
crucial for the maintenance of HSC in the vascular niche [92,94,98]. In addition to their HSC regulatory
activity, leptin receptor-cre+ MSC differentiate into osteoblasts and adipocytes in vivo [12,34], suggesting
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a main contribution in bone remodeling and turn-over of additional cell components of the niche, such
as BMA. Further, the recently identified MSC population capable of tri-lineage differentiation in vivo,
CD45− CD31− Sca-1+ CD24+, was found to largely overlap with leptin receptor-cre+ cells and Pdgfr-α+
Sca-1+ cells, and express high levels of Scf [38].
Conversely, in adult mice and humans, BMA correlate negatively with HSC function [11,99,100].
This negative correlation has been interpreted as a negative role of BMA in hematopoietic regulation,
but almost 30 years ago BMA number was reported to increase after sublethal irradiation concomitantly
with HSC proliferation [101]. HSC are reduced in adipocyte-rich vertebrae of the mouse tail compared
to the adipocyte-free vertebrae of the thorax, and accelerated engraftment following irradiation
was found using pharmacological and genetic approaches of reduced adipogenesis [11]. Back then,
no efforts were taken to understand the cross-talk interactions involved in these effects. Further,
those approaches seem to have major short-comings and affect endothelial cells in the vascular niche,
and more recently, BMA together with leptin receptor-cre+ MSC were demonstrated as the major
sources of Scf after irradiation and essential for hematopoietic recovery [12] (Figures 3 and 4). This
observation suggests that BM adipogenesis after irradiation represents a fast and efficient response
to promote emergency hematopoietic regeneration [12]. Nevertheless, intratibial transplantation
of adipocytic lineage committed cells followed by irradiation and competitive repopulation assays
inhibited hematopoietic recovery. Using this strategy, only the multipotent CD45− CD31− Sca-1+ CD24+
was capable of increased repopulation with donor-derived long-term HSC and short-term HSC [38]
(Figure 3). Future work will be needed to fully understand these seemingly contradictory results.
However, it is reasonable to hypothesize that BMA may be essential for emergency hematopoiesis, and
still be deleterious for this process, when present in unbalanced numbers.
J. Clin. Med. 2019, 8, x FOR PEER REVIEW 8 of 22 
 
f llowing irradiation was found using pharmacological and genetic approaches of reduced 
adipoge esis [11]. Back then, no efforts w re aken to und rstand the cross-talk i teractions involv d 
i  these effects. Further, those approac s seem to have major short-comings and affect endothelial 
cell  in the vascular niche, and more recently, BMA together with l ptin receptor-cre+ MSC wer  
demonstrated as the major sources of Scf af er irradiation and essential for hematopoietic recovery 
[12] (Figures 3 nd 4). Th s observation suggests that BM adipog nesis after irradiation represents a 
fast and efficient response to promote mergency hemat poietic regener tion [12]. Nevertheles , 
intratibial transplantation of adipocytic li age committed cells followed y ir diatio  and 
competitive repopulati n assays inhibited hematopoietic recovery. Using this strategy, only the 
multipotent CD45− CD31− Sca-1+ CD24+ was c pable of increased repopulation with donor-derived 
long-term HSC and short-t rm HSC [38] (Figure 3). Future work will be neede  to fully understand 
these s emingly contradictory results. However, it is easonabl  to hypothesize that BMA may be 
essential for emergency hemat poiesis, and still be deleterious for this process, when pr ent in 
unbalanc d numbers. 
 
Figure 3. Role of bone marrow adipocytes (BMA) in hematopoietic regeneration. (A) In long bones, 
irradiation and chemotherapy promote adipogenesis in a subset of leptin receptor-cre+ mesenchymal 
stromal cells (MSC) traced by Adipoq-cre. Stem cell factor (Scf) from leptin receptor-cre+ MSC and 
BMA is essential to support hematopoietic stem cell (HSC) regeneration under those conditions [12]. 
(B) Under steady-state hematopoiesis, Scf from BMA promotes HSC maintenance only in bones 
where these cells are abundant, such as caudal vertebrae. However, here, BMA have a negative impact 
on hematopoietic regeneration [12]. Further, unbalanced numbers of BMA through intratibial 
transplantation followed by irradiation inhibits hematopoietic regeneration. Using this approach, 
only transplantation of multipotent CD45− CD31− Sca-1+ CD24+ promotes hematopoietic recovery [38]. 
BMA secrete a variety of factors, and some of these have HSC regulatory activity [49]. In mice, 
adiponectin produced by BMA acts through its receptor on HSC and stimulates their proliferation 
and multipotency in vitro by activation of the p38 MAPK pathway [102]. HSC pre-treated with 
adiponectin have enhanced hematopoietic reconstitution potential after transplantation in lethally 
irradiated mice [102]. Conversely, adiponectin deficiency in mice is associated with defective 
hematopoietic regeneration after chemotherapy [103] (Figure 4). Data on adiponectin regulation in 
human hematopoiesis are scarce. Adiponectin is also produced by BMA, and it seems to inhibit 
growth of myelomonocytic progenitors [104] but stimulate myelopoiesis from HSC in vitro [105]. 
Further, recombinant adiponectin blocked adipocyte formation in long-term BM cultures and 
Fig re . ole of e rr i cytes ( ) i e atopoietic regeneration. (A) In long bones,
irra iatio a c e t r r t i esenchy al
stro al ce ls ( ) t . Ste ll t r S a
B is essential to support he atopoietic stem ce l (HSC) regeneration under those conditions [12].
( ) er t -state e atopoiesis, Scf fro ro otes S aintenance only in es
ere these cells are abundant, such s c udal ve t brae. However, here, BMA have a negative
impact on hematopoietic regeneration [12]. Further, unbalanced numbers of BMA through intratibial
tra s l t ti f ll e by irradiation inhibits hematop ietic regeneration. Using this approach, only
transplantation of multipotent CD45− CD31− Sca-1+ CD24+ promotes hematopoietic recovery [38].
J. Clin. Med. 2019, 8, 707 9 of 22
BMA secrete a variety of factors, and some of these have HSC regulatory activity [49]. In mice,
adiponectin produced by BMA acts through its receptor on HSC and stimulates their proliferation and
multipotency in vitro by activation of the p38 MAPK pathway [102]. HSC pre-treated with adiponectin
have enhanced hematopoietic reconstitution potential after transplantation in lethally irradiated mice [102].
Conversely, adiponectin deficiency in mice is associated with defective hematopoietic regeneration
after chemotherapy [103] (Figure 4). Data on adiponectin regulation in human hematopoiesis are
scarce. Adiponectin is also produced by BMA, and it seems to inhibit growth of myelomonocytic
progenitors [104] but stimulate myelopoiesis from HSC in vitro [105]. Further, recombinant adiponectin
blocked adipocyte formation in long-term BM cultures and reduced differentiation of cloned stromal
preadipocytes, through increased expression of cyclooxygenase-2 and release of prostaglandin E2 [106].
Interestingly, adiponectin inhibits B lymphopoiesis only in the presence of stromal cells through a similar
mechanism [105]. Thus, adiponectin stands out as a good candidate that mediates communication
between BMA and HSC.
J. Clin. Med. 2019, 8, x FOR PEER REVIEW 9 of 22 
 
reduced differentiation of cloned stromal preadipocytes, through increased expression of 
cyclooxygenase-2 and release of prostaglandin E2 [106]. Interestingly, adiponectin inhibits B 
lymphopoiesis only in the presence of stromal cells through a similar echanism [105]. Thus, 
adiponectin stands out as a good candidate that mediates communication between BMA and HSC. 
 
Figure 4. Summary of bone marrow adipocyte (BMA) roles in healthy hematopoiesis in vivo. (A) After 
irradiation or chemotherapy, Stem cell factor (Scf) produced by BMA is essential for hematopoietic 
regeneration [12]. (B) Adiponectin deficiency results in impaired hematopoietic regeneration after 
chemotherapy [103]. (C) Loss of the fatty acid oxidation regulator PPARδ leads to impaired 
hematopoietic regeneration after irradiation, through impaired asymmetric cell division of 
hematopoietic stem cells (HSC) [107]. (D) Under steady-state hematopoiesis, leptin or leptin signaling 
deficiency result in impaired hematopoiesis and myeloid skewing, through indirect mechanisms 
[108–110]. BMA produce and secrete adiponectin, fatty acids and leptin, but their roles in the 
hematopoietic effects described in B–D remain to be seen. 
Another interesting candidate potentially involved in coordinating adipogenesis and 
hematopoiesis is leptin, but data are still controversial. Human BMA produce leptin in vitro [111]. 
Leptin is the main adipokine produced by white adipocytes in the organism and it has pleiotropic 
effects [112–114]. Leptin-deficient (ob/ob) mice show reduced number of circulating lymphocytes and 
increased monocytes, deficient erythrocyte production in spleen and inability to fully recover 
lymphopoietic populations after irradiation insult [115,116]. Further studies of ob/ob mice and leptin 
receptor-deficient (db/db) mice demonstrated impaired hematopoiesis, BM hypocellularity and 
myeloid skewing [108,109]. Interestingly, defects can be partially ameliorated when db/db mice are 
joined to WT partners in parabiosis, through exposure to healthy blood cells and endocrine factors 
whose identity is unknown [109,110] (Figure 4). Although several hematopoietic cell types, including 
HSC, have been reported to express the long form of leptin receptor, data on the role of leptin in 
direct regulation of hematopoietic cell proliferation are contradictory [117]. In cultures of murine or 
human BM cells, human leptin failed to stimulate cell survival or proliferation [118]. However, 
another study in mice showed that leptin stimulates proliferation of murine myelocytic progenitor 
cells and synergizes with Scf to promote HSC colony formation in vitro [119]. Interestingly, leptin 
also promotes differentiation of leptin receptor-cre+ MSC towards adipose lineage at the expense of 
the osteoblastic lineage in vivo [120]. Future work will be required for a better understanding of the 
Figure 4. Summary of bone marrow adipocyte (BMA) roles in healthy hematopoiesis in vivo. (A) After
irradiation or chemotherapy, Stem cell factor (Scf) produced by BMA is essential for hematopoietic
regeneration [12]. (B) Adiponectin deficiency results in impaired hematopoietic regeneration after
chemotherapy [103]. (C) Loss of the fatty acid oxidation regulator PPARδ leads to impaired hematopoietic
regeneration after irradiation, through impaired asymmetric cell division of hematopoietic stem cells
(HSC) [107]. (D) Under steady-state hematopoiesis, leptin or leptin signaling deficiency result in impaired
hematopoiesis and myeloid skewing, through indirect mechanisms [108–110]. BMA produce and secrete
adiponectin, fatty acids and leptin, but their roles in the hematopoietic effects described in B–D remain to
be seen.
Another interesting candidate potentially involved in coordinating adipogenesis and hematopoiesis
is leptin, but data are still controversial. Human BMA produce leptin in vitro [111]. Leptin is the
main adipokine produced by white adipocytes in the organism and it has pleiotropic effects [112–114].
Leptin-deficient (ob/ob) mice show reduced number of circulating lymphocytes and increased monocytes,
deficient erythrocyte production in spleen and inability to fully recover lymphopoietic populations after
irradiation insult [115,116]. Further studies of ob/ob mice and leptin receptor-deficient (db/db) mice
demonstrated impaired hematopoiesis, BM hypocellularity and myeloid skewing [108,109]. Interestingly,
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defects can be partially ameliorated when db/db mice are joined to WT partners in parabiosis, through
exposure to healthy blood cells and endocrine factors whose identity is unknown [109,110] (Figure 4).
Although several hematopoietic cell types, including HSC, have been reported to express the long
form of leptin receptor, data on the role of leptin in direct regulation of hematopoietic cell proliferation
are contradictory [117]. In cultures of murine or human BM cells, human leptin failed to stimulate
cell survival or proliferation [118]. However, another study in mice showed that leptin stimulates
proliferation of murine myelocytic progenitor cells and synergizes with Scf to promote HSC colony
formation in vitro [119]. Interestingly, leptin also promotes differentiation of leptin receptor-cre+ MSC
towards adipose lineage at the expense of the osteoblastic lineage in vivo [120]. Future work will
be required for a better understanding of the effects of leptin in hematopoietic regulation both cell-
and non-cell-autonomously, especially in obesity where leptin production by adipocytes is increased
(Figure 5).
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Figure 5. Potential alteration of the bone marrow hematopoietic stem cell niche through unbalanced leptin
in obesity. Leptin produced by bone marrow adipocytes (BMA) stimulates adipocyte differentiation in leptin
receptor-cre+ mesenchymal stromal cells (MSC). In obesity, increased leptin production by BMA would
potentially bias MSC differentiation towards adipocyte lineage and result in hematopoietic abnormalities.
Scarce, but exciting, data are available on the role of FA secreted by BMA in hematopoiesis.
A prospective study of human BM CD133+ cells cultured in presence of EPO or G-CSF, to promote
erythropoiesis or granulopoiesis respectively, showed that the majority of resulting cells coexpress CD13
and CD36, or FA translocase, and identified this population as a common progenitor for erythroid and
myeloid lineages by colony formation ex vivo [121]. Despite expression of CD36 suggest that FA locally
released by BMA may be important for myelo/erythoid differentiation of hematopoietic progenitors,
these are able to form colonies in the absence of FA. In mouse models, FA oxidation is essential for HSC
maintenance, and loss of PPARδ (Peroxisome proliferator-activating receptor δ), important regulator of
FA oxidation that is activated by FA, or inhibition of mitochondrial FA oxidation, result in repopulation
defects after transplantation [107]. Mechanistically, inhibition of FA oxidation resulted in symmetric
HSC division, whereas PPAR-δ activation increased asymmetric cell division [107] (Figure 4). The role
of BMA in these events should be the subject of future work.
In vitro, human and mouse BMA can secrete inflammatory cytokines, particularly IL-6 and more
subtle levels of TNF-α [122,123]. Findings demonstrated that BMA promote HSC survival, supporting
HSC proliferation and differentiation after 5 weeks of coculture. In addition, BMA were found to
express CXCL12, IL-8, colony-stimulating factor 3 (CSF3), and leukemia inhibitory factor (LIF) at
similar levels to primary human BM MSC, whereas IL-3 was higher in BMA [124]. Future work should
elucidate the relative inflammatory cytokine production by BMA as compared to other major sources
in BM, and their specific role in steady-state hematopoiesis in vivo.
Finally, BMA may regulate HSC via cell-to-cell contact mechanisms, but these are not clearly
defined yet. In mice, preadipocytic cell lines and BM stromal cells treated with troglitazone to induce
adipogenesis, demonstrated enhanced HSC support in long-term serial dilution assays, compared to
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preosteoblastic cell lines and control-treated BM stromal cells, respectively [125]. In case of the
preadipocytic cell line OP9, however, their ability to support primitive HSC is reduced when achieving
complete adipocyte differentiation compared to their undifferentiated state or under osteogenic
conditions. Preadipocytic OP9 cells display enhanced HSC support in cell-to-cell contact cultures
compared to transwell, and multiple pathways seem to be involved, including Notch, Wnt, and
Hedgehog [125]. In humans, BM MSC differentiated in vitro into adipocytes failed to maintain BM
CD34+ hematopoietic progenitors in cell-to-cell cocultures, but induced their complete myeloid and
B lymphoid differentiation [126]. Conversely, others showed that the relative amount of adipocytes,
differentiated in vitro from BM MSC, supports CD34+ cell survival and inhibits their differentiation [127].
Others showed that BMA expanded in vitro as fibroblast-like fat cells inhibit granulopoiesis of CD34+
cells via neuropilin-1 through cell-to-cell contact mechanisms only, as this effect was not observed
in transwell cocultures [128]. In vivo data are urgently needed to draw conclusions on the potential
cell-to-cell communication between BMA and HSC, and whether this cross-talk may be bidirectional.
7. Role of BMA in Malignant Hematopoiesis
Mutations in the stromal HSC microenvironment as sole alterations may drive myeloproliferative
syndromes, myelodysplastic syndromes and secondary leukemia, juvenile myelomonocytic leukemia,
and AML in mice [129–132]. These findings highlight the critical role played by the HSC niche in the
initiation and development of hematological malignancies [133]. Besides, cancer cells shift their preferential
metabolism from more efficient oxidative phosphorylation to glycolylis even under aerobic conditions,
which is known as the Warburg effect [134]. The majority of cancer cells seem to be programmed to increase
glucose uptake but reduce its oxidation in the Krebs cycle, thereby becoming more dependent on additional
energy sources such as β-oxidation of FA [135,136]. Taken together, it is reasonable to hypothesize that
BMA may play an active role in the generation of a metabolic niche suitable for maintenance of malignant
blasts in the BM (Figure 6). This idea has already been demonstrated in gonadal adipose tissue, which
fuels FA oxidation in CD36+ leukemic stem cells (LSC) and protects them from chemotherapy in a mouse
model of blast crisis chronic myeloid leukemia (CML) [137].
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leukemic stem cells (LSC) and protects them from chemotherapy. Leukemic cells depend on fatty acid
(FA) oxidation as energy source, and BMA may fuel this requirement after rewire from LSC through
unknown mechanisms. Several approaches wit therapeutic otential go in this direction: genetic
disruption of the FA transporter FABP4 reduces leukemia bulk and promotes survival in acute myeloid
leukemia (AML) mouse models [138,139]; pharmacological inhibition of FA oxidation induces LSC
quiescence exit and sensitizes leukemia cells to chemotherapy in AML [140,141]; PPARγ agonists
in combination with imatinib induce LSC quiescence exit, reduce stemness and promote apoptosis
through reduction of STAT5 expression, in human chronic yeloid leuke ia [142]; and PPARγ agonists
in in vivo xenograft models of AML induce BM adipogenesis, which rescues healthy hematopoiesis
and blocks leukemic growth [29]. PPARγ agonists may improve lipid uptake and storage in BMA, and
thereby disrupt FA supply to LSC.
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However, data on the role of BMA in hematological malignancies are scarce. Human epidemiological
data show that obesity, which correlates to higher BMA number and volume, is linked to higher frequency
and mortality of leukemia [143]. Adipocytes differentiated from BM MSC in vitro promoted survival of
acute myelomonocytic leukemia cell lines and primary cells in coculture, and this was linked to increased
FA β-oxidation and upregulation of PPARγ, the FA transporter FABP4, CD36, and the antiapoptotic BCL2
gene expression [144]. Further, genetic disruption of FABP4 in AML cells or in mouse models blocked
cell proliferation in vitro and induced leukemia regression in vivo (Figure 6). FABP4 was linked to more
aggressive AML through increased IL6 expression, resulting in DNMT1 overexpression and silencing
of p15INK4B tumor-suppressor gene in AML cells [138]. Others showed that the knockdown of FABP4
increased survival in a HoxA9/Meis1-induced AML mouse model, and in vitro cocultures of adipocytes
differentiated from BM MSC together with AML blasts showed activation of lipolysis and transfer of FA
from adipocytes to AML blasts with participation of FABP4 [139] (Figure 6). This introduces the exciting
concept that LSC and/or blasts could transform the BM adipocytic niche to meet the high demand of
FA required to sustain their high proliferative rate [139]. In the same line, coculture of leukemic cell
lines with adipocytes differentiated from BM MSC showed that leukemic cells induced morphological
changes in adipocytes through secretion of growth differentiation factor 15, and as consequence of this
remodeling adipocytes promoted leukemic cell growth [145].
Thus, despite limited data on BMA, FA metabolism is emerging as a promising strategy for the
treatment of hematological malignancies. Pharmacological inhibition of FA oxidation decreased the
number of quiescent leukemia progenitor cells in approximately 50% of primary human AML samples,
sensitized leukemia cells to apoptosis induction by ABT-737 (mediated by proapoptotic Bcl-2 family
members) and, when combined with either ABT-737 or cytosine arabinoside, had therapeutic effect in
xenografts of AML cell lines in nude mice [140] (Figure 6). In human chronic lymphocytic leukemia
(CLL), PPARα expression and activity increased by treatment with the synthetic glucocorticoid
dexamethasone in vitro, and adipocyte-derived lipids, lipoproteins, and propionic acid conferred
resistance to dexamethasone [141]. PPARα and FA oxidation enzyme inhibitors increased CLL cell
death induced by dexamethasone in vitro and clearance of CLL xenografts in vivo. These findings
suggest that FA oxidation is a mechanism of resistance to glucocorticoids in CLL [141].
These data should be considered with caution though, as another recent study showed that PPARγ
agonist pioglitazone in combination with imatinib is efficient in making LSC exit quiescence to enter
apoptosis in human BCR-ABL+ CML [142]. Pioglitazone reduces STAT5 expression in LSC, thereby
reducing the expression of key STAT5 target genes involved in regulation of quiescence and stemness,
i.e., HIF2α and CITED2 [142] (Figure 6). Thus, the molecular mechanism of the therapeutic effect of
pioglitazone seems to be independent from its effects on FA metabolism, although this was not studied.
Strikingly, pioglitazone was temporarily given to three CML patients in chronic residual disease despite
continuous treatment with imatinib, and all of them achieved complete molecular remission, up to
4.7 years after withdrawal of pioglitazone [142]. Using both in vitro cocultures and in vivo xenograft
models, another recent study showed that human AML disrupts the BM adipocytic niche, resulting
in impaired myelo-erythroid maturation of healthy HSC. In vivo administration of PPARγ agonists
such as GW1929 induced BM adipogenesis, which rescued healthy hematopoietic output and repressed
leukemic growth [29] (Figure 6). The molecular mechanisms mediating communication between BMA
and healthy or malignant HSC were not studied, nor was the potential contribution of FA transfer.
Thiazolidinediones, such as pioglitazone, are PPARγ agonists that act as insulin-mimetics shifting
the energy balance towards adipocyte storage, and are currently used as antidiabetic treatment [146].
Thus, it is reasonable to hypothesize that improvement in lipid uptake and storage from adipocytes
contributes to disruption of FA supply to LSC, and that BMA play a key role in this process in the BM
in vivo. Future work should test the validity of this exciting idea. Nevertheless, thiazolidinediones
have substantial side effects that limit their clinical use. A recent study showed that genetic variations
in human adipocytes derived from subcutaneous adipocyte precursors in vitro can predict patient
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antidiabetic response to rosiglitazone [147], and these will have to be considered in the assessment of
the potential for thiazolidinediones as treatment against leukemia.
Additional mechanisms of BMA involvement in hematological malignancy progression may
include secretion of mediators, such as TNF-α, IL-6, leptin and adiponectin [148]. Leptin activates its
receptor on malignant cells from a range of myeloid and lymphoid neoplasms leading to stimulation
of cell proliferation and cytokine secretion, and protection from apoptosis, through JAK-STAT,
MAPK/ERK1/2, or PI3K signaling pathways [149]. However, the participation of BMA is unknown.
In vitro experiments showed that adipocytes differentiated from BM MSC reduced sensitivity to
doxorubicin and all-trans retinoic acid-induced apoptosis in primary acute promyelocytic leukemia
cells. This antiapoptotic effect was dependent on cell-to-cell interactions but also leptin receptor
signaling [150]. BMA are able to enhance proliferation and reduce apoptosis in coculture with multiple
myeloma cells, but leptin contribution was minor [151]. Recently, in vivo blockade of leptin receptor
signaling combined with invariant natural killer T cell stimulation resulted in higher therapeutic
efficacy against multiple myeloma [152], which highlights the limitations of in vitro studies. The case
of adiponectin is of particular interest as plasma adiponectin concentration correlates inversely with
total fat mass [153], and low adiponectin is involved in diabetes [154]. Adiponectin activates protein
kinase A, leading to decreased AKT activity and increased AMP-activated protein kinase (AMPK)
activation. AMPK then induces cell cycle arrest and apoptosis in multiple myeloma cells, at least in part
mediated by reduced expression of the enzyme acetyl-CoA-carboxylase, essential to lipogenesis [155].
Future work in vivo is required to understand the role of cytokines and adipokines secreted by BMA
in hematological malignancies.
Considering that adipose tissue from extramedullary sites such as gonads protects LSC from
chemotherapy in a mouse model of blast crisis CML [137], it is reasonable to think that BMA could
exert this function in BM. In human xenografts of T-cell acute lymphoblastic leukemia (T-ALL) into
NSG mice, T-ALL recovered from tail BM displays a non-cell-autonomous dormancy phenotype and
higher intrinsic resistance to chemotherapy, compared to T-ALL from thorax vertebrae BM [156].
Those features are similar in T-ALL recovered from gonadal adipose tissue, suggesting that BMA may
contribute to T-ALL hallmarks in tail BM [156]. Additional hints linking adipocytes to chemotherapy
resistance include that obese mice transplanted with acute lymphoblastic leukemia (ALL) cells showed
increased relapse after vincristine treatment, and lower levels of the drug in BM and blood [157,158].
Further, human and mouse ALL cell lines migrated towards conditioned media from adipocytes
differentiated in vitro from MSC cell lines, in response to CXCL12, and mouse adipose tissue explants
protected ALL cells against daunorubicin and vincristine [159]. Interestingly, mouse and human
fat explants in vitro are capable of daunorubicin uptake, and further inactivation by expression of
enzymes such as aldo-keto reductases and carbonyl reductases, which may contribute to the reduced
BM levels of the drug 2 h after its injection [160]. Future studies must determine if these data stand for
BMA as well. Of note, recently, chemotherapy-induced inhibition of adipogenesis has been suggested
as a read-out of consolidation chemotherapy efficiency in AML patients during complete remission.
Chemotherapy inhibited adipogenesis by promoting growth differentiation factor 15 secretion from
BM mononucleated cells, thereby preventing relapse in AML patients [161].
8. Conclusion
BMA are a heterogeneous cell population that shows sexual dimorphism and changes with
aging and a variety of physio-pathological conditions such as menopause, obesity, diabetes, anorexia
nervosa and leukemia. BMA are currently accepted as HSC niche cellular components, but we are only
beginning to understand the regulation exerted by BMA in steady-state hematopoiesis. Although BMA
have been considered as negative HSC regulators for a decade, more recent data showed that BMA
may be essential for emergency hematopoiesis or still be deleterious depending on the experimental
approach. BMA heterogeneity may further underlie these seeming contradictions. Future research
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should focus on accurate in vivo lineage tracing, and immunophenotypical, metabolic, and functional
characterization of cBMA and rBMA, in integrative studies on the healthy HSC niche.
Interestingly, most studies on the role of BMA in the HSC niche have focused on their potential
support of HSC survival/proliferation, with little attention to the possible facilitation of HSC differentiation.
However, myeloid skewing is a common event in obesity, diabetes, myeloid malignancies, and aging [162];
all conditions with increased BMA. Considering that extramedullary hematopoiesis in adipose tissue is
preferentially axed towards the myeloid lineage [163,164], the involvement of BMA in such a process in
the BM under health and disease should be subject of future work.
Finally, early hints suggest that LSC could transform BMA to provide a suitable metabolic niche
for their malignant growth that also protects them from chemotherapy. However, most data on this
topic are derived from adipocytes differentiated in vitro from BM MSC and cocultures with leukemic
cells, which represents a major limitation and requires urgent in vivo confirmation. If this exciting
idea is valid, then BMA could be seen as potential therapeutic targets to restore hematopoiesis in
the context of malignancy. Indeed, pioneering studies showed therapeutic value for PPARγ agonists
in CML patients and AML xenograft models, and BMA participated at least in the beneficial effects
of these compounds against AML. However, the underlying molecular mechanisms remain largely
unknown and need further investigation.
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